Coya Therapeutics Completes Full Enrollment of 120 Patients in Phase 2/3 ALSTARS Trial for COYA 302 in ALS
COYA sits 36% above its 52-week low of $3.71.
Summary
Coya Therapeutics announced full enrollment of 120 patients in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with topline data expected in early Q2 2027.
Key Events · Product Development and Regulatory · COYA
-
Full Enrollment Achieved
All 120 planned patients have been enrolled in the Phase 2/3 ALSTARS trial evaluating COYA 302 for ALS, up from 100 patients reported on September 15, 2026.
-
Topline Data Timeline Set
Topline data from the 24-week double-blind treatment phase is anticipated in early Q2 2027, providing a concrete readout window for the primary endpoint (ALSFRS-R change from baseline to Week 24).
-
Trial Design Confirmed
The trial randomizes approximately 120 patients 1:1:1 to two COYA 302 dosing regimens or placebo, followed by a 24-week blinded active-treatment extension phase providing up to 48 weeks of data.
-
Prior Milestone Context
This follows the 100-patient enrollment milestone disclosed on September 15, 2026, and represents the completion of the recruitment phase for the company's lead clinical program.
Analysis · COYA · Life Sciences
Coya Therapeutics has fully enrolled the planned 120 patients in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, a milestone that moves the program from recruitment to the data-readout phase. The company also provided a specific topline data timeline of early Q2 2027, giving investors a concrete catalyst date. This is a meaningful de-risking event for the lead clinical program, as full enrollment reduces execution risk and sets the clock for the pivotal efficacy readout.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COYA was trading at $5.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $112.8M. The 52-week trading range was $3.71 to $7.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.